Fundamental Analysis of CYTOKINETICS INC(NASDAQ:CYTK) stock

Fundamental Rating

Overall CYTK gets a fundamental rating of 2 out of 10. We evaluated CYTK against 588 industry peers in the Biotechnology industry. CYTK has a bad profitability rating. Also its financial health evaluation is rather negative. CYTK is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CYTK has reported negative net income.

CYTK had a negative operating cash flow in the past year.

In the past 5 years CYTK always reported negative net income.

In the past 5 years CYTK reported 4 times negative operating cash flow.

1.2 Ratios

CYTK's Return On Assets of -63.84% is on the low side compared to the rest of the industry. CYTK is outperformed by 61.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	-63.84%
ROE	N/A
ROIC	N/A

ROA(3y)-42.59%

ROA(5y)-38.72%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CYTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CYTK has more shares outstanding

Compared to 5 years ago, CYTK has more shares outstanding

The debt/assets ratio for CYTK is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -1.38, we must say that CYTK is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CYTK (-1.38) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.38

ROIC/WACCN/A

WACC8.63%

2.3 Liquidity

CYTK has a Current Ratio of 6.12. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 6.12, CYTK is in the better half of the industry, outperforming 62.91% of the companies in the same industry.

CYTK has a Quick Ratio of 6.12. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CYTK (6.12) is better than 63.25% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.12
Quick Ratio	6.12

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CYTK have decreased strongly by -29.15% in the last year.

CYTK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.04%.

The Revenue for CYTK have been decreasing by -24.89% on average. This is quite bad

EPS 1Y (TTM)-29.15%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q4.83%

Revenue 1Y (TTM)-92.04%

Revenue growth 3Y-48.71%

Revenue growth 5Y-24.89%

Revenue growth Q2Q-14.69%

3.2 Future

CYTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.12% yearly.

CYTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 136.35% yearly.

EPS Next Y16.62%

EPS Next 2Y17.57%

EPS Next 3Y22.47%

EPS Next 5Y21.12%

Revenue Next Year-66.37%

Revenue Next 2Y176.2%

Revenue Next 3Y201.11%

Revenue Next 5Y136.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.

Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CYTK's earnings are expected to grow with 22.47% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.57%

EPS Next 3Y22.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CYTK!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYTOKINETICS INC

NASDAQ:CYTK (4/19/2024, 4:28:59 PM)

After market: 67.55 0 (0%)

67.55

+0.55 (+0.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.96B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-63.84%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.12
Quick Ratio	6.12
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-29.15%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y16.62%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-92.04%

Revenue growth 3Y-48.71%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CYTOKINETICS INC (CYTK)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens